Carcinoid Syndrome Diarrhea Treatment Market

SKU: DM2105 | Last Updated On: Sep 28 2022 | Available Formats

> Carcinoid Syndrome Diarrhea Treatment Market Expected to reach at a high CAGR of 13.2% by 2029: DataM Intelligence

Carcinoid Syndrome Diarrhea Treatment Market is segmented By Therapy Type (Chemotherapy, Somatostatin Analog (SSA) Therapy, Others), By End-user (Cancer centers, Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Carcinoid Syndrome Diarrhea Treatment Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 13.2% during the forecast period (2022-2029).

Carcinoid Syndrome Diarrhea Treatment Market

Metrics

Details

Market CAGR

13.2%

Segments Covered

By Therapy Type, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

Carcinoid syndrome is a paraneoplastic syndrome comprising signs and symptoms secondary to carcinoid tumors. The syndrome includes flushing and diarrhea, and less frequently, vomiting, heart failure, and bronchoconstriction. It is caused by the endogenous secretion of kallikrein and serotonin.

Market Dynamics

The major driving forces are the new product approvals, government and regulatory bodies ' support for developing orphan drugs, the increasing incidence of hormonal disorders, and the rising disease prevalence.

The promising carcinoid syndrome diarrhea pipeline is expected to drive market growth.

The promising carcinoid syndrome diarrhea pipeline is expected to boost the market. For instance, according to the ClinicalTrials.Gov, currently, a phase 2 study evaluating a proprietary amino acid-based medical food (Enterade) in patients with the quality of life-limiting diarrhea due to carcinoid syndrome and other neuroendocrine tumors (NET) was sponsored by Lowell Anthony, MD, in collaboration of Entrinsic Bioscience Inc. is active. Also, a randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose-response of Paltusotine treatment in subjects with carcinoid syndrome is currently recruiting, sponsored by Crinetics Pharmaceuticals Inc. and is estimated to be completed by November 2024. Thus, the rising interventional clinical studies are fueling the global market growth.

The lack of approved drugs hinders global carcinoid syndrome diarrhea treatment market growth.

However, the low availability of therapeutic options for the treatment, low awareness, and side effects associated with the therapy is likely to hamper the market. The onset of side effects related to the therapy restricts the market growth. For instance, some side effects are bradyarrhythmia, dysrhythmia, hyperglycemia, hypothyroidism, cholelithiasis, pancreatitis, and angioedema.

Industry analysis.

The global carcinoid syndrome diarrhea treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, and pipeline analysis.

Segment Analysis

The chemotherapy segment is expected to dominate the carcinoid syndrome diarrhea treatment market throughout the forecast period (2022-2029).

The chemotherapy segment is expected to grow rapidly over the forecast period (2022-2029), owing to FDA-approved drugs. Chemotherapy involves anti-cancer drugs injected into a vein or a muscle or taken by the mouth to kill cancer cells. The drugs enter the blood and reach almost all body parts, making this treatment useful for a few types of cancers that have spread. Some of the chemotherapeutic drugs used to treat GI carcinoid tumors include Capecitabine (Xeloda), Doxorubicin (Adriamycin), rapid heartbeat, Etoposide (VP-16), and Dacarbazine (DTIC). Some tumors, like high-grade tumors, may be treated with more than one drug. For this, 5-FU plus streptozocin, 5-FU plus doxorubicin, or oxaliplatin plus capecitabine may be used. Thus, the presence of FDA-approved chemotherapeutic drugs is driving the market growth.

Geographical Analysis

The North American region holds the largest market share of the global carcinoid syndrome diarrhea treatment market.

North America dominated the global carcinoid syndrome diarrhea treatment market in 2021. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the high disease prevalence, regulatory approvals, and better reimbursement policies. The increasing prevalence of the disease is expected to accelerate market growth over the forecast period. For instance, an estimation from the American Society of Clinical Oncology (ASCO) indicates that more than 12,000 people in the United States are diagnosed with NET yearly, and approximately 175,000 people live with this. The count of people diagnosed with this type of tumor has been growing over the years. Also, it affects both males and females in equal numbers. The increasing prevalence of the disease is, in turn, increasing demand for carcinoid syndrome diarrhea treatment devices. Thus, the rising prevalence of carcinoid tumors in the region is driving the market. In addition, the presence of non-profit organizations for the treatment is expected to bolster market growth over the forecast period. For instance, The Carcinoid Cancer Foundation began as the Carcinoid Tumor and Serotonin Research Foundation when the NIH fund for rare cancers was terminated. It is a non-profit organization chartered by New York to support research and education on carcinoids and other neuroendocrine cancers.

Competitive Landscape

The major players operating in the global carcinoid syndrome diarrhea treatment market are Lexicon Pharmaceuticals, Inc., Novartis International AG (Sandoz), Ipsen Biopharmaceuticals, Inc., Pharmascience Inc, Omega Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Entrinsic Health Solutions, Inc, Sirtex Medical Limited, BTG International Ltd and Sun Pharmaceuticals Industries Ltd. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the global carcinoid syndrome diarrhea treatment market. For instance, on 16 August 2022, Lexicon Pharmaceuticals entered into data collaboration with AC Bioscience. Also, on January 31, 2020, Sandoz completed the acquisition of Aspen’s Japanese operations.

Novartis AG

Overview:

Novartis AG is a leading global pharmaceutical manufacturing company based in Basel, Switzerland and Cambridge, Massachusetts, United States. Novartis AG was founded in 1996 through the merger of Ciba-Geigy and Sandoz.

Product Portfolio:

 Novartis AG’s product portfolio for carcinoid syndrome diarrhea treatment has Sandostatin LAR Depot (octreotide acetate) injections in 10mg, 20mg, and 30mg strength.

The global carcinoid syndrome diarrhea treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Trending Topics

Chemotherapy Induced Peripheral Neuropathy Treatment Market

Anti-Diarrheal Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest